Literature DB >> 8422689

Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma.

G J Peters1, J Lankelma, R M Kok, P Noordhuis, C J van Groeningen, C L van der Wilt, S Meyer, H M Pinedo.   

Abstract

Concentrations of 5-fluorouracil (5-FU) and its active metabolite 5-fluoro-2'-deoxy-5'-monophosphate (FdUMP) were measured in biopsy specimens of tumor tissue, normal mucosa, metastatic liver nodules, and normal liver tissue obtained from 39 patients and in two murine colon tumors (colon 26 and colon 38) after a single injection of 5FU at a therapeutic dose (500 mg/m2 and 100 mg/kg, respectively). These data were compared with plasma concentrations. Peak plasma concentrations (300-500 microM) of 5FU were comparable in human and murine plasma. The half-life of plasma elimination (during the period from 15 to 120 min) in both mouse and man ranged from 10 to 20 min, whereas at between 2 and 8 h, plasma concentrations varied from 0.1 to 1 microM, the half-life being about 100 min. In both species, 5FU could be measured in plasma at concentrations ranging from 0.01 to 1 microM for several days after 5FU treatment. 5FU concentrations in tissue samples obtained from 14 patients were measured during the time range of 1-6 h, those in samples taken from 7 patients, during the interval of 19-27 h; and those in samples obtained from 18 patients, within the interval of 40-48 h after injection. 5FU tumor concentrations varied between 0.78-21.6, 0.44-6.1, and 0.17-10.8 mumol/kg wet wt., respectively. Some of the 48-h samples were obtained from patients who had received leucovorin plus 5FU; coadministration of leucovorin did not alter 5FU tissue concentrations. At between 4 and 48 h, the tissue concentration/plasma concentration ratio was at least 10. 5FU concentrations in murine tumors were measured for up to 10 days after 5FU administration, with plateau 5FU tumor concentrations being about 50 mumol/kg wet wt. in colon 38 and about 200 mumol/kg wet wt. in colon 26 at 2 h after treatment; after 4 days, values of 0.5 and 4.8 mumol/kg, respectively, were obtained and after 10 days, respective concentrations of 0.1 and 0.07 mumol/kg were detected. The FdUMP concentrations measured in colon 26 and colon 38 tumors were 214 and 46 pmol/g, respectively, at 2 h after 5FU administration, and these values subsequently decreased to about 15 pmol/g in both tumors. In human tumors the initial FdUMP concentration ranged from 10 to 1000 pmol/g; at later time points the level of FdUMP was just above the detection limit of the assay. In liver metastases, high 5FU concentrations seemed to be related to high levels of FdUMP, which was likely of importance for the antitumor effect.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8422689     DOI: 10.1007/bf00685670

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  40 in total

1.  Tissue homogenization using a micro-dismembrator for the measurement of enzyme activities.

Authors:  G J Peters; E J Laurensse; A Leyva; H M Pinedo
Journal:  Clin Chim Acta       Date:  1986-07-30       Impact factor: 3.786

2.  The analysis of 5-fluorouracil in human plasma by gas chromatography-negative ion chemical ionization mass spectrometry (GC-NICIMS) with stable isotope dilution.

Authors:  C D Bates; D G Watson; N Willmott; H Logan; J Goldberg
Journal:  J Pharm Biomed Anal       Date:  1991       Impact factor: 3.935

3.  Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule.

Authors:  C J van Groeningen; H M Pinedo; J Heddes; R M Kok; A P de Jong; E Wattel; G J Peters; J Lankelma
Journal:  Cancer Res       Date:  1988-12-01       Impact factor: 12.701

4.  Kinetic modeling of in vivo--nuclear magnetic resonance spectroscopy data: 5-fluorouracil in liver and liver tumors.

Authors:  R E Port; P Bachert; W Semmler
Journal:  Clin Pharmacol Ther       Date:  1991-05       Impact factor: 6.875

5.  pH dependence of 5-fluorouracil uptake observed by in vivo 31P and 19F nuclear magnetic resonance spectroscopy.

Authors:  J L Guerquin-Kern; F Leteurtre; A Croisy; J M Lhoste
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

6.  The relationship between plasma pharmacokinetics and tissue metabolites of 5-fluorouracil (5-FU) in patients with colorectal cancer.

Authors:  P J Finan; E M Chisholm; L Woodhouse; G R Giles
Journal:  Eur J Surg Oncol       Date:  1987-08       Impact factor: 4.424

7.  Pharmacokinetics of 5-fluorouracil infusions in the rat: comparison with man and other species.

Authors:  J M Collins
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 8.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

9.  In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil.

Authors:  G J Peters; J van Dijk; E Laurensse; C J van Groeningen; J Lankelma; A Leyva; J C Nadal; H M Pinedo
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

10.  Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo.

Authors:  P M McSheehy; M J Prior; J R Griffiths
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

View more
  28 in total

1.  Relationship between Fas/FasL expression and apoptosis of colon adenocarcinoma cell lines.

Authors:  Z H Peng; T H Xing; G Q Qiu; H M Tang
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

2.  Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.

Authors:  Ellen J B Derissen; Bart A W Jacobs; Alwin D R Huitema; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2016-03-02       Impact factor: 4.335

3.  Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion.

Authors:  Shenghui He; Patrick J Roberts; Jessica A Sorrentino; John E Bisi; Hannah Storrie-White; Renger G Tiessen; Karenann M Makhuli; William A Wargin; Henko Tadema; Ewoud-Jan van Hoogdalem; Jay C Strum; Rajesh Malik; Norman E Sharpless
Journal:  Sci Transl Med       Date:  2017-04-26       Impact factor: 17.956

4.  Optimization of an aqueous tablet-coating process containing carboxymethylated Cassia fistula gum.

Authors:  Parshu Ram Rai; Ashok Kumar Tiwary; Vikas Rana
Journal:  AAPS PharmSciTech       Date:  2012-02-24       Impact factor: 3.246

5.  Mismatch repair proficiency and in vitro response to 5-fluorouracil.

Authors:  J M Carethers; D P Chauhan; D Fink; S Nebel; R S Bresalier; S B Howell; C R Boland
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

6.  Antitumor Efficacy and Toxicity of 5-Fluorouracil-Loaded Poly(Lactide Co-glycolide) Pellets.

Authors:  Nattawut Leelakanok; Sean M Geary; Aliasger K Salem
Journal:  J Pharm Sci       Date:  2017-10-12       Impact factor: 3.534

7.  High glucose modulates antiproliferative effect and cytotoxicity of 5-fluorouracil in human colon cancer cells.

Authors:  Yi-Shing Ma; I-Ping Yang; Hsiang-Lin Tsai; Ching-Wen Huang; Suh-Hang Hank Juo; Jaw-Yuan Wang
Journal:  DNA Cell Biol       Date:  2013-11-27       Impact factor: 3.311

8.  Pharmacokinetic application of a bio-analytical LC-MS method developed for 5-fluorouracil and methotrexate in mouse plasma, brain and urine.

Authors:  Vaishnavi Ganti; Ellen A Walker; Swati Nagar
Journal:  Biomed Chromatogr       Date:  2013-03-12       Impact factor: 1.902

9.  Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil.

Authors:  L Thiberville; P Compagnon; N Moore; G Bastian; M O Richard; M F Hellot; C Vincent; M M Kannass; S Dominique; C Thuillez
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Establishing a model for assessing DNA damage in murine brain cells as a molecular marker of chemotherapy-associated cognitive impairment.

Authors:  Evgeny Krynetskiy; Natalia Krynetskaia; Diana Rihawi; Katarzyna Wieczerzak; Victoria Ciummo; Ellen Walker
Journal:  Life Sci       Date:  2013-04-06       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.